Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Gene expression profiling of gastric mucosa in mice lacking CCK and gastrin receptors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Natriuretic peptides and cerebral hemodynamics

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Adropin: a new regulatory peptide in cardiovascular endocrinology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  4. Cardiac C-type natriuretic peptide gene expression and plasma concentrations in neonatal piglets

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Gut hormones - Team workers or solo trippers?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Gut Mucosal Gene Expression and Metabolic Changes After Roux-en-Y Gastric Bypass Surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
The incretin hormone, glucose-dependent insulinotropic polypeptide (GIP, previously known as gastric inhibitory polypeptide), is rapidly degraded to the biologically inactive metabolite GIP (3-42) in the circulation, but little is known about the kinetics of the intact hormone and the metabolite and whether differences exist between patients with type 2 diabetes mellitus and healthy subjects. We examined eight type 2 diabetic patients (six men, two women); mean (range) age: 59 (48-69) years; BMI: 31.6 (26.0-37.7) kg/m2; HbA1C: 9.0 (8.2-13.2) %; fasting plasma glucose (FPG): 10.0 (8.3-13.2) mmol/l and 8 healthy subjects matched for age, gender and BMI. An intravenous bolus injection of GIP (7.5 nmol) was given and venous blood samples were drawn the following 45 minutes. Peak concentrations of total GIP (intact+metabolite, mean+/-SEM) and intact GIP (in brackets) were 920+/-91 (442+/-52) pmol/l in the type 2 diabetic patients and 775+/-68 (424+/-30) pmol/l in the healthy subjects (NS). GIP was eliminated rapidly with the clearance rate for intact GIP being 2.3+/-0.2 l/min in the type 2 diabetic patients and 2.4+/-0.2 l/min in the healthy subjects (NS). The volumes of distributions were similar in the two groups and ranged from 8 to 21 l per subject. The primary metabolite, GIP 3-42, generated through the action of dipeptidyl peptidase IV (DPP-IV), was eliminated with a mean half-life of 17.5 and 20.5 min in patients and healthy subjects (NS). CONCLUSION: Elimination of GIP is similar in obese type 2 diabetic patients and matched healthy subjects. Differences in elimination of GIP and its primary metabolite, therefore, do not seem to contribute to the defective insulinotropic effect of GIP in type 2 diabetes.
OriginalsprogEngelsk
TidsskriftRegulatory Peptides
Vol/bind137
Udgave nummer3
Sider (fra-til)168-72
Antal sider5
ISSN0167-0115
DOI
StatusUdgivet - 10 dec. 2006

ID: 32268289